2023

1. Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model (Frontiers in Pharmacology, (2023), 14, (1021535), 10.3389/fphar.2023.1021535)

   Frontiers in Pharmacology

2. Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

   Frontiers in Pharmacology, Vol. 14

3. Novel Loss-of-Function KCNA5 Variants in Pulmonary Arterial Hypertension

   American Journal of Respiratory Cell and Molecular Biology, Vol. 69, Núm. 2, pp. 147-158

4. Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities

   PLoS pathogens, Vol. 19, Núm. 1, pp. e1011063